GDR vs. AGL, YGEN, ABDX, PRM, VRCI, GENI, DMTR, LLAI, LLA, and IDHC
Should you be buying genedrive stock or one of its competitors? The main competitors of genedrive include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), Verici Dx (VRCI), GENinCode (GENI), Deepmatter Group (DMTR), LungLife AI (LLAI), LLA.L,0P0001T9GN,0 (LLA), and Integrated Diagnostics (IDHC). These companies are all part of the "diagnostics & research" industry.
genedrive vs. Its Competitors
ANGLE (LON:AGL) and genedrive (LON:GDR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
ANGLE has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, genedrive has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500.
genedrive has lower revenue, but higher earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.
In the previous week, ANGLE had 2 more articles in the media than genedrive. MarketBeat recorded 2 mentions for ANGLE and 0 mentions for genedrive. genedrive's average media sentiment score of 0.00 beat ANGLE's score of -0.24 indicating that genedrive is being referred to more favorably in the news media.
genedrive received 59 more outperform votes than ANGLE when rated by MarketBeat users. Likewise, 72.67% of users gave genedrive an outperform vote while only 62.46% of users gave ANGLE an outperform vote.
ANGLE has a net margin of -890.91% compared to genedrive's net margin of -1,412.18%. ANGLE's return on equity of -76.01% beat genedrive's return on equity.
18.8% of ANGLE shares are held by institutional investors. Comparatively, 0.3% of genedrive shares are held by institutional investors. 16.2% of ANGLE shares are held by company insiders. Comparatively, 14.8% of genedrive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
ANGLE currently has a consensus price target of GBX 40, suggesting a potential upside of 485.99%. Given ANGLE's stronger consensus rating and higher probable upside, equities analysts clearly believe ANGLE is more favorable than genedrive.
Summary
ANGLE beats genedrive on 12 of the 18 factors compared between the two stocks.
Get genedrive News Delivered to You Automatically
Sign up to receive the latest news and ratings for GDR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GDR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
genedrive Competitors List
Related Companies and Tools
This page (LON:GDR) was last updated on 6/11/2025 by MarketBeat.com Staff